Shunichiro Kuramitsu

Nagoya Medical Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Carl H. June

University of Pennsylvania

Sangya Agarwal

University of Pennsylvania

Marco Ruella

University of Pennsylvania

Charly R. Good

University of Pennsylvania

Shelley L. Berger

University of Pennsylvania

Nathan Singh

Washington University in St. Louis

Pranali Ravikumar

University of Pennsylvania

Shannon L. Maude

University of Pennsylvania

Elena J. Orlando

Novartis (United States)

Stephan A. Grupp

Children's Hospital of Philadelphia

Cooperative Institutions

Nagoya University

140

University of Pennsylvania

Nagoya University Hospital

Japanese Red Cross Nagoya Daini Hospital

Nagoya Medical Center

National Hospital Organization

California University of Pennsylvania

Komaki City Hospital

Nagoya City University

Parker Institute for Cancer Immunotherapy

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

An NK-like CAR T cell transition in CAR T cell dysfunction

Cell (2021)

Charly R. Good M. Ángela Aznar Shunichiro Kuramitsu Parisa Samareh Sangya Agarwal

Mesothelin

10.1016/j.cell.2021.11.016

Cite

Citations (254)

Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving tocilizumab: illustrative case

Journal of Neurosurgery Case Lessons (2022)

Masasuke Ohno Shunichiro Kuramitsu Akari Iwakoshi Junya Yamaguchi Fumiharu Ohka

Although the risk of developing malignant lymphoma is higher in patients with rheumatoid arthritis (RA) than in the general population, primary central nervous system lymphoma (PCNSL) in patients with RA is extremely rare. In recent years, there has been concern that biological disease-modifying antirheumatic drugs (bDMARDs), widely administered to patients with RA, might increase the risk of cancer development. The authors report the first case of PCNSL in a patient with RA receiving the bDMARD tocilizumab.A 70-year-old man who was diagnosed with RA in 2010 was treated with low-dose methotrexate (MTX) from 2010 to 2015. Tocilizumab was commenced in 2012. In 2018, he developed gait disturbances, and gadolinium-enhanced magnetic resonance imaging showed multiple contrast-enhanced lesions in the basal ganglia and brain stem. Stereotactic brain biopsy led to the diagnosis of diffuse large B-cell lymphoma, and finally PCNSL was diagnosed. He was treated with five courses of MTX 3.5 g/m2, and his disease has been in remission for 34 months.Low-dose MTX and bDMARDs are associated with the concern of increased cancer risk in patients with RA. Because tocilizumab has been in use for a relatively short time, further accumulation of cases and careful follow-up are necessary.

Tocilizumab

10.3171/case22256

Cite

Citations (0)

Figure S3 from Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction

Nathan Singh Yong Gu Lee Olga Shestova Pranali Ravikumar Katharina E. Hayer

Persistent exposure to WT leukemia causes progressive CART19 dysfunction.

10.1158/2159-8290.22535498

Cite

Citations (0)

Adoptive Immunotherapy for the Treatment of Glioblastoma: Progress and Possibilities

Immunotherapy (2016)

Shunichiro Kuramitsu Akane Yamamichi Fumiharu Ohka Kazuya Motomura Masahito Hara

Patients with glioblastoma have a very poor prognosis. Adoptive cellular therapy (ACT) is defined as the collection of circulating or tumor-infiltrating lymphocytes, their selection, modification, expansion and activation, and their re-administration to patients in order to induce antitumor activity. Although various ACTs have been attempted, most failed to improve the outcome. Immune checkpoint blockade antibodies and T cell engineering with tumor-specific chimeric antigen receptors suggest the emergence of a new era of immunotherapy. Here, we summarize approaches with ACTs using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to develop these therapies. The mechanisms by which gliomas modulate and evade the immune system are also discussed.

Adoptive Cell Transfer

Adoptive immunotherapy

Immune checkpoint

10.2217/imt-2016-0076

Cite

Citations (8)

Time course of tumorigenesis of a newly developed sporadic hemangioblastoma in an elderly patient: illustrative case

Journal of Neurosurgery Case Lessons (2024)

Yu Sugiyama Shunichiro Kuramitsu Kaoru Eguchi Masashi Ito Ryo Ando

BACKGROUND von Hippel-Lindau disease–associated hemangioblastomas (HBs) account for 20%–30% of all HB cases, with the appearance of new lesions often observed in the natural course of the disease. By comparison, the development of new lesions is rare in patients with sporadic HB. OBSERVATIONS A 65-year-old man underwent clipping for an unruptured aneurysm of the anterior communicating artery. Fourteen years later, follow-up magnetic resonance imaging (MRI) revealed a strongly enhanced mass in the right cerebellar hemisphere, diagnosed as a sporadic HB. A retrospective review of MRI studies obtained over the follow-up period revealed the gradual development of peritumoral edema and vascularization before mass formation. LESSONS Newly appearing high-intensity T2 lesions in the cerebellum may represent a preliminary stage of tumorigenesis. Careful monitoring of these patients would be indicated, which could provide options for early treatment to improve patient outcomes.

Hemangioblastoma

Cerebellar hemisphere

Mass/lesion

10.3171/case23757

Cite

Citations (0)

Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma

Molecular Therapy — Oncolytics (2022)

Lushun Chalise Akira Kato Masasuke Ohno Sachi Maeda Akane Yamamichi

Podoplanin

10.1016/j.omto.2022.07.006

Cite

Citations (56)

Efficacy of intraoperative irrigation with artificial cerebrospinal fluid in chronic subdural hematoma surgery: study protocol for a multicenter randomized controlled trial

Trials (2024)

Yoshitaka Nagashima Yoshio Araki Kazuki Nishida Shunichiro Kuramitsu Kenichi Wakabayashi

The surgical techniques for treatment of chronic subdural hematoma (CSDH), a common neurosurgical condition, have been discussed in a lot of clinical literature. However, the recurrence proportion after CSDH surgery remains high, ranging from 10 to 20%. The standard surgical procedure for CSDH involves a craniostomy to evacuate the hematoma, but irrigating the hematoma cavity during the procedure is debatable. The authors hypothesized that the choice of irrigation fluid might be a key factor affecting the outcomes of surgery. This multicenter randomized controlled trial aims to investigate whether intraoperative irrigation using artificial cerebrospinal fluid (ACF) followed by the placement of a subdural drain would yield superior results compared to the placement of a subdural drain alone for CSDH.

Clinical endpoint

Chronic Subdural Hematoma

Postoperative hematoma

10.1186/s13063-023-07889-7

Cite

Citations (2)

Figure S1 from Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction

Nathan Singh Yong Gu Lee Olga Shestova Pranali Ravikumar Katharina E. Hayer

Impairment of death receptor signaling results in resistance to CART19.

10.1158/2159-8290.22535504

Cite

Citations (0)